Navamedic has entered into an exclusive agreement with the Danish company Re5 ApS for Nordic distribution of the Re5-Neuro Treatment System (Re5-NTS).
Developed by University of Copenhagen researchers in collaboration with Karolinska Institutet in Stockholm, the Re5-NTS device is used as a complementary treatment combined with standard treatment of patients with refractory depression.
Navamedic CEO Tom Rönnlund said: “Navamedic is very excited to announce the partnership with Re5 ApS for Nordic distribution of Re5-NTS, bringing an innovative, non-invasive and safe treatment option to patients suffering from refractory depression.
“The device, which uses technology based on Transcranial Pulsed Electric Fields, has shown very encouraging results in clinical studies.
“Navamedic sees great value in an unmet, significant medical need for this product, and begins the Nordic roll-out of the device in Denmark to psychiatric clinics.”
The technology of the device is based on Transcranial Pulsed Electro Magnetic Fields (T-PEMF) which is the process of issuing electrical pulses to the brain.
It consists of a pulse generator and seven coils attached with Velcro tape and placed on the patient’s head.
The coils trigger electromagnetic pulses to the brain which results in an enhanced brain activity.
The electric pulses generated from the Re5–NTS coils mimic the electric activity present in brain tissue to activate nerve cells to secrete important signaling molecules related to growth and activity.
The process of brain stimulation with electric pulses thereby resulting in an increased brain activity.